Patients with MSI‐high pancreatic tumors have a longer overall survival time than MSI‐low and microsatellite stable pancreatic tumors. MSI‐high tumors also have poor differentiation and wild‐type KRAS and p53. This evidence concerns the gene KRAS and pancreatic neoplasm.